Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for type 2 diabetes mellitus (T2DM) and obesity due to their efficacy in glycemic control, weight reduction, and cardiovascular risk mitigation. Despite these benefits, concerns persist regarding their potential adverse effects [1]. Emerging evidence suggests a potential association between GLP-1 RA use, particularly semaglutide, and nonarteritic anterior ischemic optic neuropathy (NAION), a serious ophthalmic event and a significant cause of vision loss characterized by sudden, painless visual impairment, primarily in middle-aged and elderly individuals [1,2].
